These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28131216)

  • 1. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
    J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
    de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
    Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
    Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
    Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    Cabre P; Mejdoubi M; Jeannin S; Merle H; Plumelle Y; Cavillon G; Smadja D; Marignier R;
    J Neurol; 2018 Apr; 265(4):917-925. PubMed ID: 29455361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
    Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
    J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
    Ahn SH; Kim SM; Sung JJ
    Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review.
    Abbadessa G; Miele G; Maida E; Minervini G; Lavorgna L; Bonavita S
    Mult Scler Relat Disord; 2022 Jul; 63():103926. PubMed ID: 35661568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.
    Tahara M; Oeda T; Okada K; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Mult Scler Relat Disord; 2022 Apr; 60():103730. PubMed ID: 35287025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rituximab in refractory neuromyelitis optica.
    Collongues N; Brassat D; Maillart E; Labauge P; Ouallet JC; Carra-Dalliere C; Moreau T; Bourre B; Papeix C; Brochet B; Audoin B; Vukusic S; de Seze J; Marignier R;
    Mult Scler; 2016 Jun; 22(7):955-9. PubMed ID: 26362900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
    Pellkofer HL; Krumbholz M; Berthele A; Hemmer B; Gerdes LA; Havla J; Bittner R; Canis M; Meinl E; Hohlfeld R; Kuempfel T
    Neurology; 2011 Apr; 76(15):1310-5. PubMed ID: 21482945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
    Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    Annovazzi P; Capobianco M; Moiola L; Patti F; Frau J; Uccelli A; Centonze D; Perini P; Tortorella C; Prosperini L; Lus G; Fuiani A; Falcini M; Martinelli V; Comi G; Ghezzi A
    J Neurol; 2016 Sep; 263(9):1727-35. PubMed ID: 27286847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Nasir M; Hone L; Tallantyre E; Kelly P; Leite MI; Robertson N; Bestwick J; Huda S; Palace J; Dobson R
    Mult Scler Relat Disord; 2024 May; 85():105528. PubMed ID: 38479046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
    Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
    Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.